The Central Social Insurance Medical Council, better known as Chuikyo, appears to see the need to set up new dosage…
HOME > COMMENTARY
COMMENTARY
- Drastically Changing Marketing Strategy - The Best Strategy for Company Differentiation -
April 22, 2002
- BARKER ON DRUGS (3)
March 11, 2002
- BARKER ON DRUGS
February 18, 2002
- Comarketing as a Marketing Strategy Option -1-
January 21, 2002
- Comarketing as a Marketing Strategy Option -2-
January 21, 2002
- Barker on Drugs (1)
January 14, 2002
- Why Foreign-affiliated Companies Cannot Expand Their Market Share in Japan
July 9, 2001
- < Special Contribution >What Are the Requirements for a Japanese Blockbuster Product? -2-
May 21, 2001
- < Special Contribution >What Are the Requirements for a Japanese Blockbuster Product? -1-
May 21, 2001
- Forecasting JapaneseDrug Industry Growth in FY2001
March 26, 2001
- -1-
February 26, 2001
- -2-
February 26, 2001
- -1-
February 5, 2001
- -2-
February 5, 2001
- Advanced Technology and Segmentation of Companies
January 15, 2001
- Don't Write Us Oldies Off!
January 15, 2001
- Changing Japanese Heathcare Scene - Health Care Transition Leads Evaluation of Pharma Market -
January 15, 2001
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…